earningsconfidence high
LENZ Therapeutics reports Q1 2026 net loss $41.5M, VIZZ product sales $1.7M
LENZ Therapeutics, Inc.
2026-Q1 EPS
reported -$1.32
vs consensus -$1.09
▼ miss
(-21.0%)
- Q1 2026 product sales $1.7M from ~25,000 paid prescriptions, 19% increase over Q4 2025.
- Launched DTC campaign with Sarah Jessica Parker; website traffic up 10x; pilot TV advertising in April 2026.
- Submitted MAA to EMA (March 2026) and MHRA (April 2026) for VIZZ; fourth ex-U.S. partnership with Lunatus in Jan 2026.
- Net loss $41.5M ($1.32/share) vs. $14.6M ($0.53/share) in Q1 2025; cash $258.4M to fund operations to positive cash flow.
- Sales force expanding from 88 to 117 by end of Q2 2026; launched ECP direct sales initiative in April 2026.
item 2.02item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.